X-ACT

Regimen

Experimental
Oral capecitabine 1,250 mg/m² BID days 1–14 Q3W × 8 cycles
Control
Bolus fluorouracil + leucovorin (Mayo Clinic regimen)

Population

Stage III colon cancer after curative resection (N=1,987), adjuvant capecitabine vs IV 5-FU/LV.

Key finding

Capecitabine non-inferior to bolus FL for DFS (HR upper bound <1.20, P<0.001); relapse-free survival HR 0.86 (P=0.04) favoring capecitabine; fewer adverse events with capecitabine. Established oral capecitabine as equivalent single-agent adjuvant alternative to IV 5-FU/LV.

Source: PMID 15987918

Timeline

    Guideline citations

    • NCCN Colon (p.99)